Compare · ARGX vs IMCR
ARGX vs IMCR
Side-by-side comparison of argenx SE (ARGX) and Immunocore Holdings plc (IMCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IMCR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 32.9x IMCR ($1.93B).
- Over the past year, ARGX is up 44.0% and IMCR is up 14.2% - ARGX leads by 29.8 points.
- ARGX has been more active in the news (11 items in the past 4 weeks vs 6 for IMCR).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Immunocore Holdings plc
- Price
- $1019.71+0.82%
- $37.30+1.72%
- Market cap
- $63.27B
- $1.93B
- 1M return
- +14.62%
- +10.44%
- 1Y return
- +43.97%
- +14.19%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest IMCR
- Analyst resumed coverage on Immunocore with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc
- SEC Form 10-Q filed by Immunocore Holdings plc
- Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Immunocore reports second quarter financial results and provides a business update
- Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
- Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
- SEC Form 4 filed by Director Kaul Siddharth
- SEC Form 4 filed by Director Pao William